Review




Structured Review

Biogen Inc mouse anti-ifnar1 aa3 mab
Mouse Anti Ifnar1 Aa3 Mab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-ifnar1 aa3 mab/product/Biogen Inc
Average 90 stars, based on 1 article reviews
mouse anti-ifnar1 aa3 mab - by Bioz Stars, 2026-06
90/100 stars

Images



Similar Products

90
Biogen Inc mouse anti-ifnar1 aa3 mab
Mouse Anti Ifnar1 Aa3 Mab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-ifnar1 aa3 mab/product/Biogen Inc
Average 90 stars, based on 1 article reviews
mouse anti-ifnar1 aa3 mab - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

98
Cell Signaling Technology Inc aa3
Aa3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aa3/product/Cell Signaling Technology Inc
Average 98 stars, based on 1 article reviews
aa3 - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier

99
Cell Signaling Technology Inc rat anti plp aa3
Rat Anti Plp Aa3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat anti plp aa3/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
rat anti plp aa3 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

90
Biogen Inc monoclonal antibodies (mabs) aa3
(A) Graphic representation of the relative antiproliferative potencies of IFN-α2 and IFN-β in the human cell lines 2fTGH (fibrosarcoma), WISH (amniotic), MDA231 (breast cancer), and Daudi (B lymphoma) and the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) described in this study. EC50s (pM) for IFN-α2 are plotted against the ratio of the EC50 of IFN-α2 to that of IFN-β for each cell line (Table ​(Table1).1). (B) Levels of IFNAR1 and IFNAR2 in the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) and in the parental 2fTGH cells. Surface IFNAR1 and IFNAR2 were quantified by FACS analysis using <t>MAbs</t> <t>AA3</t> and CD118, respectively. Dark gray area, isotypic control; light gray area, 2fTGH; black line, U5-low/low, U5-low/hi, or U5-hi/hi. Of note, these clones exhibited similar forward scatter values, as determined by FACS analysis, indicating that the increases observed are due to changes in surface receptor density and not cell volume. (C) Analysis of the expression level of Jak/Stat pathway components in 2fTGH cells and the U5-derived clones. Total cell lysates (30 μg) were analyzed by Western blotting with the indicated Abs. Loading was evaluated by measuring Akt levels.
Monoclonal Antibodies (Mabs) Aa3, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibodies (mabs) aa3/product/Biogen Inc
Average 90 stars, based on 1 article reviews
monoclonal antibodies (mabs) aa3 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Biogen Inc aa3 mab
(A) Graphic representation of the relative antiproliferative potencies of IFN-α2 and IFN-β in the human cell lines 2fTGH (fibrosarcoma), WISH (amniotic), MDA231 (breast cancer), and Daudi (B lymphoma) and the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) described in this study. EC50s (pM) for IFN-α2 are plotted against the ratio of the EC50 of IFN-α2 to that of IFN-β for each cell line (Table ​(Table1).1). (B) Levels of IFNAR1 and IFNAR2 in the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) and in the parental 2fTGH cells. Surface IFNAR1 and IFNAR2 were quantified by FACS analysis using <t>MAbs</t> <t>AA3</t> and CD118, respectively. Dark gray area, isotypic control; light gray area, 2fTGH; black line, U5-low/low, U5-low/hi, or U5-hi/hi. Of note, these clones exhibited similar forward scatter values, as determined by FACS analysis, indicating that the increases observed are due to changes in surface receptor density and not cell volume. (C) Analysis of the expression level of Jak/Stat pathway components in 2fTGH cells and the U5-derived clones. Total cell lysates (30 μg) were analyzed by Western blotting with the indicated Abs. Loading was evaluated by measuring Akt levels.
Aa3 Mab, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aa3 mab/product/Biogen Inc
Average 90 stars, based on 1 article reviews
aa3 mab - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


(A) Graphic representation of the relative antiproliferative potencies of IFN-α2 and IFN-β in the human cell lines 2fTGH (fibrosarcoma), WISH (amniotic), MDA231 (breast cancer), and Daudi (B lymphoma) and the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) described in this study. EC50s (pM) for IFN-α2 are plotted against the ratio of the EC50 of IFN-α2 to that of IFN-β for each cell line (Table ​(Table1).1). (B) Levels of IFNAR1 and IFNAR2 in the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) and in the parental 2fTGH cells. Surface IFNAR1 and IFNAR2 were quantified by FACS analysis using MAbs AA3 and CD118, respectively. Dark gray area, isotypic control; light gray area, 2fTGH; black line, U5-low/low, U5-low/hi, or U5-hi/hi. Of note, these clones exhibited similar forward scatter values, as determined by FACS analysis, indicating that the increases observed are due to changes in surface receptor density and not cell volume. (C) Analysis of the expression level of Jak/Stat pathway components in 2fTGH cells and the U5-derived clones. Total cell lysates (30 μg) were analyzed by Western blotting with the indicated Abs. Loading was evaluated by measuring Akt levels.

Journal:

Article Title: Receptor Density Is Key to the Alpha2/Beta Interferon Differential Activities

doi: 10.1128/MCB.01808-08

Figure Lengend Snippet: (A) Graphic representation of the relative antiproliferative potencies of IFN-α2 and IFN-β in the human cell lines 2fTGH (fibrosarcoma), WISH (amniotic), MDA231 (breast cancer), and Daudi (B lymphoma) and the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) described in this study. EC50s (pM) for IFN-α2 are plotted against the ratio of the EC50 of IFN-α2 to that of IFN-β for each cell line (Table ​(Table1).1). (B) Levels of IFNAR1 and IFNAR2 in the three U5-derived clones (U5-low/low, U5-low/hi, and U5-hi/hi) and in the parental 2fTGH cells. Surface IFNAR1 and IFNAR2 were quantified by FACS analysis using MAbs AA3 and CD118, respectively. Dark gray area, isotypic control; light gray area, 2fTGH; black line, U5-low/low, U5-low/hi, or U5-hi/hi. Of note, these clones exhibited similar forward scatter values, as determined by FACS analysis, indicating that the increases observed are due to changes in surface receptor density and not cell volume. (C) Analysis of the expression level of Jak/Stat pathway components in 2fTGH cells and the U5-derived clones. Total cell lysates (30 μg) were analyzed by Western blotting with the indicated Abs. Loading was evaluated by measuring Akt levels.

Article Snippet: Surface receptor levels were monitored as described in reference 18 , using monoclonal antibodies (MABs) AA3 (BiogenIdec, Boston) and CD118 (PBL, Piscataway, NJ), which are specific for IFNAR1 and IFNAR2 respectively.

Techniques: Derivative Assay, Clone Assay, Expressing, Western Blot